FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to novel compounds of formula (I) which possess the properties of an inhibitor of viral RNA polymerase activity and replication of RNA viruses, such as orthomixovirus, paramyxovirus, arenavirus, bunyavirus, flavivirus, filovirus, togavirus, picornavirus and coronavirus, adenovirus, rhinovirus, hepatitis A virus, hepatitis C virus, poliomyelitis virus, measles virus, Ebola virus, Coxsackie virus, West Nile fever virus, smallpox virus, yellow fever virus, Dengue Fever virus, influenza A virus, influenza B virus, Lassa virus, lymphocytic choriomeningitis virus, Junin virus et al. In the formula (I)
L1, L2 and L3 each independently, are a bond or a linker -C(R0)2-O-; L4, L5 and L6 each is a bond; R0, independently for each occurrence, is H or (C1-C6)alkyl; R1, R2 and R3 each independently, are selected from the group consisting of H; aminoacyl, wherein independently for each occurrence, aminoacyl -C(=O)CH(NH2)(CH2)nCHR30R31, where n is 0 or 1; and R30 and R31 each independently are H or (C1-C6) alkyl; acyl, wherein independently for each occurrence, acyl is -C(=O)R40, where R40 is (C1-C6) alkyl; R10OC(O)-; phosphoryl; and aminophosphoryl, wherein independently for each occurrence, aminophosphoryl is -P(=O)(OR50)NR51R52, where R50 is selected from the group consisting of phenyl, naphthyl and -(CH2)mSC(=O)C(CH3)2CH2OH, m is 1 or 2, R51 is H or (C1-C6) alkyl, and R52 is selected from the group consisting of H, (C1-C6) alkyl, benzyl and -CR60R61C(=O)OR62, where R60 and R61 each independently are H or (C1-C6) alkyl; and R62 is H or (C1-C6) alkyl; or R1 and R2, taken together, or R2 and R3, taken together, may be selected from the group consisting of carbonyl, phosphoryl and (C1-C6) alkylphosphoryl; R4, R5 and R6 are H; R7 is H; R10, independently for each occurrence, is H or (C1-C6)alkyl.
EFFECT: invention relates to novel compounds which possess the properties of an inhibitor of viral RNA polymerase activity and replication of RNA viruses.
30 cl, 2 dwg, 19 ex, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
METHODS AND COMPOSITIONS FOR INHIBITING POLYMERASE | 2011 |
|
RU2718690C2 |
SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
BETA-LACTAMASE INHIBITORS | 2009 |
|
RU2445314C9 |
ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
Authors
Dates
2018-05-21—Published
2013-04-17—Filed